Buys
Open market- Shares
- Avg price
- Total value
Chris Degnan - Chief Financial Officer at UroGen Pharma Ltd.
Issuer-level insider activity
- Role
- Chief Financial Officer
- Issuer ticker
- URGN on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Chris Degnan in UroGen Pharma Ltd.
Sells
Open market- Shares
- -2,203
- Avg price
- $16.85
- Total value
- -$37,121
Net
Past year- Shares
- -2,203
- Share %
- -100%
- Total value
- -$37,121
Reported holdings for Chris Degnan in UroGen Pharma Ltd.
Form 4 holding
Chief Financial Officer
UroGen Pharma Ltd.
- Security class
- Ordinary Shares
- Shares / value
- 2,280
- Estimated value
- $38,418
- Report date
- 08 Oct 2025
- Price
- $16.85
- Ownership
- Direct
Form 4 holding
Chief Financial Officer
UroGen Pharma Ltd.
- Security class
- Restricted Stock Units
- Shares / value
- 32,609
- Estimated value
- Report date
- 31 Jan 2026
- Price
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
Transaction history for Chris Degnan in UroGen Pharma Ltd.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.